Short Interest in Merck KGaA Surges by 234.9% in December

Short interest in Merck KGaA (OTCMKTS:MKKGY) saw a dramatic increase of 234.9% in December 2023. As of December 15, the total short interest reached 241,637 shares, up from 72,150 shares recorded at the end of November. This surge indicates heightened bearish sentiment among investors, although short selling currently constitutes approximately 0.0% of the company’s total shares outstanding.

The days-to-cover ratio, which indicates how many days it would take to cover all short positions based on the average daily trading volume, currently stands at 0.9 days. This calculation is based on an average daily trading volume of 280,839 shares.

Merck KGaA’s stock performance reflected a modest uptick on December 15, with shares trading at $28.51, an increase of $0.06 from the previous day. A total of 80,966 shares changed hands, falling short of the average volume of 114,320 shares. Financial metrics show that the company maintains a current ratio of 1.49, a quick ratio of 0.97, and a debt-to-equity ratio of 0.36. Merck KGaA enjoys a market capitalization of $18.42 billion, with a price-to-earnings (P/E) ratio of 11.36 and a P/E/G ratio of 5.71. Over the past year, the stock has fluctuated between a low of $24.32 and a high of $31.80. The company’s 50-day moving average stands at $27.00, while the 200-day moving average is $26.34.

In its most recent quarterly earnings report released on November 13, 2023, Merck KGaA posted earnings per share (EPS) of $0.81, surpassing analyst expectations of $0.54 by $0.27. The firm achieved a net margin of 13.92% and a return on equity of 10.07%, with total revenues amounting to $6.17 billion, exceeding the consensus estimate of $6.08 billion. Analysts predict that Merck KGaA will report an EPS of $1.87 for the current fiscal year.

Merck KGaA, headquartered in Darmstadt, Germany, is a multinational science and technology company with a legacy that dates back to 1668. The organization focuses on developing and manufacturing products across healthcare, life sciences, and electronics sectors. It is important to distinguish that Merck KGaA operates independently from the U.S.-based pharmaceutical firm Merck & Co..

The healthcare division of Merck KGaA is dedicated to the development of prescription medicines and services, particularly in oncology, immunology, neurology (including treatments for multiple sclerosis), and fertility.

For those interested in staying updated on Merck KGaA’s latest news and analyst ratings, a subscription to relevant financial newsletters is recommended to receive concise daily summaries.